iRhythm Technologies Announces First Quarter 2024 Financial Results

May 2, 2024

SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024.

First Quarter 2024 Financial Highlights

  • Revenue of $131.9 million, a 18.4% increase compared to first quarter 2023
  • Gross margin of 66.3%, a 160-basis point decline compared to first quarter 2023
  • Unrestricted cash, cash equivalents and marketable securities of $569.1 million as of March 31, 2024
  • Increased fiscal year 2024 revenue guidance to a range of $578 million to $588 million

Recent Operational Highlights

  • Over half a million registrations during the first quarter driven by continued growth from primary care prescribers, further penetration within existing accounts, and expansion into near-record new account openings for Zio long-term continuous monitoring services
  • Announced collaboration with Epic’s Aura platform to drive efficiencies through EMR integration and enable streamlined access to Zio services through improved operational efficiency for clinicians
  • Presented heart failure prediction algorithm data at ACC in April, demonstrative of the scientific evidence our teams and academic partners are generating in support of EKG as a critical vital sign for predictive clinical insights
  • Upcoming data presentation at the Heart Rhythm Society (HRS) in Boston, MA, from May 16 - 19, 2024

"During the first quarter of 2024, we were very pleased with the continued momentum in our core markets that enabled record unit volumes as well as strong new account openings," said Quentin Blackford, president and chief executive officer of iRhythm. "First quarter revenue growth of 18.4% year-over-year was driven by sustained growth in our existing accounts but also significant contribution from accounts opened within the past twelve months. We have been very encouraged with the growing traction within the primary care channel, highlighting Zio's value proposition as a workflow efficiency tool to expand ambulatory cardiac monitoring capacity within large care networks. When combined with progress that we are making with electronic health integration and emerging clinical evidence on the potential for EKG data to provide future clinical insights, we could not be more excited about our positioning to create significant value for patients, clinicians, healthcare systems, and stakeholders."

First Quarter Financial Results
Revenue for the first quarter of 2024 was $131.9 million, up 18.4% from $111.4 million during the same period in 2023. The increase was driven by growth in demand for Zio services.

Gross profit for the first quarter of 2024 was $87.5 million, up 15.6% from $75.7 million during the same period in 2023, while gross margin was 66.3%, down from 67.9% during the same period in 2023. The increase in gross profit was primarily due to increased volume of Zio services provided due to higher demand. The decrease in gross margin was primarily due to accelerated recognition of the cost of our legacy Zio XT components associated with our ongoing Zio monitor commercial launch as well as costs related to scaling and training newly onboarded clinical cardiac technicians at our San Francisco IDTF center of excellence.

Operating expenses for the first quarter of 2024 were $125.7 million, compared to $115.2 million for the same period in 2023. Adjusted operating expenses for the first quarter of 2024 were $125.7 million, compared to $109.5 million during the same period in 2023. This increase in adjusted operating expenses resulted primarily from increased headcount-related and third-party costs to support growth in operations and the further development, enhancement, and functionality of our current and future product offerings.

Net loss for the first quarter of 2024 was $45.7 million, or a diluted loss of $1.47 per share, compared with net loss of $39.1 million, or a diluted loss of $1.29 per share, for the same period in 2023. Adjusted net loss for the first quarter of 2024 was $38.1 million, or a diluted loss of $1.23 per share, compared with an adjusted net loss of $33.4 million, or a diluted loss of $1.10 per share, for the same period in 2023.

Unrestricted cash, cash equivalents, and marketable securities were $569.1 million as of March 31, 2024.

2024 Annual Guidance
iRhythm projects revenue for the full year 2024 to grow approximately 17% to 19% compared to prior year results, ranging from approximately $578 million to $588 million. Gross margin for the full year 2024 is expected to range from 68% to 69% and adjusted EBITDA margin for the full year 2024 is expected to range from approximately 3% to 4% of revenues.

Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Use of Non-GAAP Financial Measures
We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release, including adjusted EBITDA, adjusted net loss, adjusted net loss per share and adjusted operating expenses. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. See the schedules attached to this press release for additional information and reconciliations of such non-GAAP financial measures. We have not reconciled our adjusted operating expenses and adjusted EBITDA estimates for full year 2024 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of adjusted operating expenses and adjusted EBITDA estimates is not available without unreasonable effort.

Adjusted EBITDA excludes non-cash operating charges for stock-based compensation, depreciation and amortization as well as non-operating items such as interest income, interest expense, impairment and restructuring charges, loss on extinguishment of debt, and business transformation costs.

We exclude the following items from non-GAAP financial measures for adjusted net loss, adjusted net loss per share and adjusted operating expenses:

  • impairment and restructuring charges,
  • loss on extinguishment of debt, and
  • business transformation costs to scale the organization.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding financial guidance, market opportunity, ability to penetrate the market, anticipated productivity improvements and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including those on the Form 10-Q expected to be filed on or about May 2, 2024. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact
Stephanie Zhadkevich
(919) 452-5430
investors@irhythmtech.com

iRhythm Media Contact
Saige Smith
(262) 289-7065
irhythm@highwirepr.com

IRHYTHM TECHNOLOGIES, INC.
Condensed Consolidated Balance Sheets
(unaudited)
(In thousands, except par value)
 
 March 31, 2024 December 31, 2023
    
Assets   
Current assets:   
Cash and cash equivalents$520,421  $36,173 
Marketable securities 48,671   97,591 
Accounts receivable, net 89,712   61,484 
Inventory 14,873   13,973 
Prepaid expenses and other current assets 13,778   21,591 
Total current assets 687,455   230,812 
Property and equipment, net 112,274   104,114 
Operating lease right-of-use assets 48,073   49,317 
Restricted cash, long-term 8,358    
Goodwill 862   862 
Other assets 52,733   48,039 
Total assets$909,755  $433,144 
Liabilities and Stockholders’ Equity   
Current liabilities:   
Accounts payable$8,440  $5,543 
Accrued liabilities 70,044   83,362 
Deferred revenue 3,068   3,306 
Operating lease liabilities, current portion 15,289   15,159 
Total current liabilities 96,841   107,370 
Long-term senior convertible notes 644,076    
Debt, noncurrent portion    34,950 
Other noncurrent liabilities 908   1,012 
Operating lease liabilities, noncurrent portion 77,640   79,715 
Total liabilities 819,465   223,047 
Stockholders’ equity:   
Preferred stock, $0.001 par value – 5,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023     
Common stock, $0.001 par value – 100,000 shares authorized; 31,326 shares issued and 31,097 shares outstanding at March 31, 2024, respectively; and 30,954 shares issued and outstanding at December 31, 2023 31   31 
Additional paid-in capital 806,621   855,784 
Accumulated other comprehensive loss (89)  (112)
Accumulated deficit (691,273)  (645,606)
Treasury stock, at cost; 229 and 0 shares at March 31, 2024 and December 31, 2023, respectively (25,000)   
Total stockholders’ equity 90,290   210,097 
Total liabilities and stockholders’ equity$909,755  $433,144 
        

 

IRHYTHM TECHNOLOGIES, INC.
Condensed Consolidated Statements of Operations
(unaudited)
(In thousands, except per share data)
 
  Three Months Ended March 31,
   2024   2023 
Revenue, net $131,929  $111,436 
Cost of revenue  44,413   35,755 
Gross profit  87,516   75,681 
Operating expenses:    
Research and development  16,994   14,842 
Selling, general and administrative  108,660   100,343 
Total operating expenses  125,654   115,185 
Loss from operations  (38,138)  (39,504)
Interest expense  (2,860)  (950)
Interest and other income, net  2,952   1,432 
Loss on extinguishment of debt  (7,589)   
Loss before income taxes  (45,635)  (39,022)
Income tax provision  32   87 
Net loss $(45,667) $(39,109)
Net loss per common share, basic and diluted $(1.47) $(1.29)
Weighted-average shares, basic and diluted  31,033   30,297 
         

 

IRHYTHM TECHNOLOGIES, INC.
Reconciliation of GAAP to Non-GAAP Financial Information
(unaudited)
(in thousands, except per share data)
 
  Three Months Ended March 31,
   2024   2023 
Adjusted EBITDA reconciliation    
Net loss $(45,667) $(39,109)
Interest expense  2,860   950 
Interest income  (3,057)  (1,434)
Income tax provision  32   87 
Depreciation and amortization  5,131   3,576 
Stock-based compensation  20,991   18,251 
Business transformation costs     5,686 
Loss on extinguishment of debt  7,589    
Adjusted EBITDA $(12,121) $(11,993)
         

 

  Three Months Ended March 31,
   2024   2023 
Adjusted net loss reconciliation    
Net loss, as reported $(45,667) $(39,109)
Business transformation costs     5,686 
Loss on extinguishment of debt  7,589    
Adjusted net loss $(38,078) $(33,423)
     
Adjusted net loss per share reconciliation    
Net loss per share, as reported $(1.47) $(1.29)
Business transformation costs per share     0.19 
Loss on extinguishment of debt  0.24    
Adjusted net loss per share $(1.23) $(1.10)
Weighted-average shares, basic and diluted  31,033   30,297 
     
Adjusted operating expense reconciliation    
Operating expense, as reported $125,654  $115,185 
Business transformation costs     (5,686)
Adjusted operating expense $125,654  $109,499 
         

Primary Logo

Source: iRhythm

Email Alerts

Sign up to receive e-mail alerts whenever iRhythm posts new information to the site.